Dithranol-loaded nanostructured lipid carrier-based gel ameliorate psoriasis in imiquimod-induced mice psoriatic plaque model

Sathe, Priyadarshini; Raju, S.; Kommineni, Nagavendra; Raza, Kaisar; Khan, Wahid

doi:10.1080/03639045.2019.1576722

Cited by 73 publications

(30 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In previously conducted studies, psoriasis area severity index (PASI) score, ear thickness measurements, histological staining, splenic involvement and the role of inflammatory cytokines have been very well established in this model [ 3 , 4 , 6 ]. This model has already been successfully exploited for ex vivo or in vivo screening of various conventional topical formulations [ 7 ] as well as novel drug nanovectors, such as poly(lactic acid) [ 8 ] or poly(lactic-co-glycolic acid) [ 9 ] nanoparticles, liposomes [ 10 ], lipid-carrier based gels [ 11 ] or β-cyclodextrin complexes [ 12 ]. However, there are certain parameters like skin barrier disruption, systemic inflammation, or the correlation between symptoms severity and skin concentration in IMQ that are not fully described for this model in the literature.…”

Section: Introductionmentioning

confidence: 99%

Advanced Characterization of Imiquimod-Induced Psoriasis-Like Mouse Model

et al. 2020

View full text Add to dashboard Cite

Many autoimmune disorders such as psoriasis lead to the alteration of skin components which generally manifests as unwanted topical symptoms. One of the most widely approved psoriasis-like animal models is the imiquimod (IMQ)-induced mouse model. This representation mimics various aspects of the complex cutaneous pathology and could be appropriate for testing topical treatment options. We perform a thorough characterization of this model by assessing some parameters that are not fully described in the literature, namely a precise description of skin disruption. It was evaluated by transepidermal water loss measurements and analyses of epidermis swelling as a consequence of keratinocyte hyperproliferation. The extent of neo-angiogenesis and hypervascularity in dermis were highlighted by immunostaining. Moreover, we investigated systemic inflammation through cytokines levels, spleen swelling and germinal centers appearance in draining lymph nodes. The severity of all parameters was correlated to IMQ concentration in skin samples. This study outlines new parameters of interest useful to assess this model. We highlight the skin barrier disruption and report a systemic inflammatory reaction occurring at distance both in spleen and lymph nodes. These newly identified biological endpoints could be exploited to investigate the efficacy of therapeutic candidates for psoriasis and more extensively for several other skin inflammatory diseases.

show abstract

Section: Introductionmentioning

confidence: 99%

Advanced Characterization of Imiquimod-Induced Psoriasis-Like Mouse Model

et al. 2020

View full text Add to dashboard Cite

show abstract

“…[30] Even dithranol which is less and less used by dermatologists due to its toxic dermatitis reactions and staining of clothes could be successfully loaded in a liposomal gel, showing a significant decrease in disease activity by PASI score and led to profound reduction of IL-17, IL-22 and IL-23 cytokine levels in skin homogenates of imiquimod-treated psoriasis mice. [31] Another novel approach consists in loading NPs with known systemic immunosuppressive agents. As opposed to NPs alone, methotrexate-loaded Au-NPs administered topically significantly reduced keratinocyte proliferation, epidermal thickness and infiltration with cytotoxic CD8 lymphocytes in the skin of the imiquimod-induced psoriasis-like mouse model.…”

Section: Topi C Al Nps Comple Xed With P Olyphenol S Suppre Ss Inflmentioning

confidence: 99%

How can nanoparticle‐based technologies revolutionize the topical therapy in psoriasis?

Sindrilaru

Filip

Scharffetter‐Kochanek

et al. 2020

Experimental Dermatology

View full text Add to dashboard Cite

show abstract

“…Sathe and colleagues developed and tested a dithranol‐loaded liposomic gel (particle size = 203.3 ± 1.20 nm, PDI = 0.29 ± 0.04 and zeta = −0.97 ± 0.08) on IMQ‐treated mice model finding an optimal antipsoriatic property as testified by the significantly decreased PASI and IL‐17, IL‐22, IL‐23 serum levels compared to nontreated controls (Sathe, Saka, Kommineni, Raza, & Khan, ).…”

Section: Nanotherapeutics For Psoriasis: Nanocarriers Nanodrugs and mentioning

confidence: 99%

Nanodermatology‐based solutions for psoriasis: State‐of‐the art and future prospects

Damiani

Pacifico

Linder

et al. 2019

Dermatologic Therapy

View full text Add to dashboard Cite

Nanodermatology is an emerging, multidisciplinary science, arising from the convergence of nanotechnology, pharmacology, physics/biophysics, chemistry/biochemistry, chemical engineering, material science, and clinical medicine. Nanodermatology deals with (a) skin biology, anatomy, and physiology at the nanoscale (“skin nanobiology”), (b) diagnosis performed by means of novel diagnostic devices, assisted by nanobiotechnologies (“nanodiagnosis”), and (c) treatment through innovative therapeutic agents, including phototherapy (“photonanotherapy”/“photonanodermatology”) and systemic/topical drug administration (“nanotherapy”) at the nanoscale, and drug delivery—such as transdermal or dermal drug delivery (TDDD/DDD)—enhanced and improved by nanostructures and nanodrugs (“nanodrug delivery”). Nanodermatology, as a super‐specialized branch of dermatology, is a quite recent specialty: the “Nanodermatology Society” founded by the eminent dermatologist Dr. Adnan Nasir, was established in 2010, with the aim of bringing together different stakeholders, including dermatologists, nanotechnology scientists, policy‐makers and regulators, as well as students and medical residents. Psoriasis has a prevalence of 2–3% worldwide and imposes a severe clinical and societal burden. Nanodermatology‐based solutions appear promising for the proper treatment and management of psoriasis, assisting and enhancing different steps of the process of health‐care delivery: from the diagnosis to the therapeutics, paving the way for a personalized approach, based on the specific dysregulated biomarkers.

show abstract

Dithranol-loaded nanostructured lipid carrier-based gel ameliorate psoriasis in imiquimod-induced mice psoriatic plaque model

Cited by 73 publications

References 52 publications

Advanced Characterization of Imiquimod-Induced Psoriasis-Like Mouse Model

Advanced Characterization of Imiquimod-Induced Psoriasis-Like Mouse Model

How can nanoparticle‐based technologies revolutionize the topical therapy in psoriasis?

Nanodermatology‐based solutions for psoriasis: State‐of‐the art and future prospects

Contact Info

Product

Resources

About